The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor

Karpova, D; Dauber, K; Spohn, G; Chudziak, D; Wiercinska, E; Schulz, M; Pettit, A R; Levesque, J P; Romagnoli, B; Patel, K; Chevalier, E; Dembowsky, K; Bonig, H
December 2013
Leukemia (08876924);Dec2013, Vol. 27 Issue 12, p2322
Academic Journal
Mobilized blood has supplanted bone marrow (BM) as the primary source of hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Pharmacologically enforced egress of hematopoietic stem cells from BM, or mobilization, has been achieved by directly or indirectly targeting the CXCL12/CXCR4 axis. Shortcomings of the standard mobilizing agent, granulocyte colony-stimulating factor (G-CSF), administered alone or in combination with the only approved CXCR4 antagonist, Plerixafor, continue to fuel the quest for new mobilizing agents. Using Protein Epitope Mimetics technology, a novel peptidic CXCR4 antagonist, POL5551, was developed. In vitro data presented herein indicate high affinity to and specificity for CXCR4. POL5551 exhibited rapid mobilization kinetics and unprecedented efficiency in C57BL/6 mice, exceeding that of Plerixafor and at higher doses also of G-CSF. POL5551-mobilized stem cells demonstrated adequate transplantation properties. In contrast to G-CSF, POL5551 did not induce major morphological changes in the BM of mice. Moreover, we provide evidence of direct POL5551 binding to hematopoietic stem and progenitor cells (HSPCs) in vivo, strengthening the hypothesis that CXCR4 antagonists mediate mobilization by direct targeting of HSPCs. In summary, POL5551 is a potent mobilizing agent for HSPCs in mice with promising therapeutic potential if these data can be corroborated in humans.


Related Articles

  • Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. Walkley, Carl R.; Fero, Matthew L.; Chien, Wei-Ming; Purton, Louise E.; McArthur, Grant A. // Nature Cell Biology;Feb2005, Vol. 7 Issue 2, p172 

    Haematopoietic stem cells (HSCs) are capable of shifting from a state of relative quiescence under homeostatic conditions to rapid proliferation under conditions of stress. The mechanisms that regulate the relative quiescence of stem cells and its association with self-renewal are unclear, as is...

  • Immune activation modulates hematopoiesis through interactions between CD27 and CD70. Nolte, Martijn A.; Arens, Ramon; van Os, Ronald; van Oosterwijk, Michiel; Hooibrink, Berend; van Lier, René A. W.; van Oers, Marinus H. J. // Nature Immunology;Apr2005, Vol. 6 Issue 4, p412 

    The differentiation of hematopoietic stem cells into mature blood cell lineages is tightly regulated. Here we report that CD27, which is expressed on stem and early progenitor cells in bone marrow, can be important in this process. Deletion of CD27 increased the myeloid colony-forming potential...

  • Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Ott, Marion G.; Schmidt, Manfred; Schwarzwaelder, Kerstin; Stein, Stefan; Siler, Ulrich; Koehl, Ulrike; Glimm, Hanno; Kühlcke, Klaus; Schilz, Andrea; Kunkel, Hana; Naundorf, Sonja; Brinkmann, Andrea; Deichmann, Annette; Fischer, Marlene; Ball, Claudia; Pilz, Ingo; Dunbar, Cynthia; Yang Du; Jenkins, Nancy A.; Copeland, Neal G. // Nature Medicine;Apr2006, Vol. 12 Issue 4, p401 

    Gene transfer into hematopoietic stem cells has been used successfully for correcting lymphoid but not myeloid immunodeficiencies. Here we report on two adults who received gene therapy after nonmyeloablative bone marrow conditioning for the treatment of X-linked chronic granulomatous disease...

  • Enhancing bone marrow regeneration by SALL4 protein. Wenbin Liao; Aguila, Jerell R.; Yixin Yao; Jianchang Yang; Gary Zieve; Yongping Jiang; Avila, Cecilia; Lisa Senzel; Lai, Raymond; Dazhong Xu; Wei Dai; Yupo Ma // Journal of Hematology & Oncology;2013, Vol. 6 Issue 1, p1 

    Hematopoietic stem cells (HSCs) are widely used in transplantation therapy to treat a variety of blood diseases. The success of hematopoietic recovery is of high importance and closely related to the patient's morbidity and mortality after Hematopoietic stem cell transplantation (HSCT). We have...

  • Stem cells: The road not taken. Hock, Hanno; Orkin, Stuart H. // Nature;6/2/2005, Vol. 435 Issue 7042, p573 

    This article presents information related to haematopoietic stem cells (HSCs). These cells reside in bone marrow and are the source of the various blood-cell types. The classic experiments of I.L. Weissman showed that HSCs give rise to progenitor populations that can be isolated prospectively by...

  • Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue. Dickhut, Andreas; Schwerdtfeger, Rainer; Kuklick, Larissa; Ritter, Markus; Thiede, Christian; Neubauer, Andreas; Brendel, Cornelia // Annals of Hematology;Nov2005, Vol. 84 Issue 11, p722 

    Mesenchymal stem cells (MSC) obtained from human bone marrow have been described as adult stem cells with the ability of extensive self-renewal and clonal expansion, as well as the capacity to differentiate into various tissue types and to modulate the immune system. Some data indicate that...

  • The vascular niche: home for normal and malignant hematopoietic stem cells. Doan, P L; Chute, J P // Leukemia (08876924);Jan2012, Vol. 26 Issue 1, p54 

    Hematopoietic stem cells (HSCs) are uniquely capable of self-renewal and provision of all of the mature elements of the blood and immune system throughout the lifetime of an individual. HSC self-renewal is regulated by both intrinsic mechanisms and extrinsic signals mediated via specialized...

  • Immunology: Blood lines redrawn. Graf, Thomas // Nature;4/10/2008, Vol. 452 Issue 7188, p702 

    The article focuses on the central aspect of blood-cell differentiation. The main components of the blood are red cells, whites cells and platelets. These were produced from the haematopoietic stem cells as a common source. On the other hand, the white cells or the leukocytes functions as an...

  • Outcome of unrelated transplants in patients with multiple myeloma. Ballen, K. K.; King, R.; Carston, M.; Kollman, C.; Nelson, G.; Lim, S.; Reece, D.; Giralt, S.; Vesole, D. H. // Bone Marrow Transplantation;Apr2005, Vol. 35 Issue 7, p675 

    Summary:The outcome of patients with multiple myeloma treated with standard therapy is disappointing, with a historical median survival of 3 years. Although high-dose therapy with autologous stem cell transplant has improved treatment outcomes, cure is unlikely. Allogeneic transplant provides a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics